Adjuvant IFNα2 therapy of melanoma

Lancet

Volumn 351, Issue 9120, 1998, Pages 1901-1903

  Kirkwood, J M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; HISTOCHEMISTRY; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MELANOMA; META ANALYSIS; METHODOLOGY; PRIORITY JOURNAL; SHORT SURVEY; SUBCUTANEOUS DRUG ADMINISTRATION; DISEASE FREE SURVIVAL; METASTASIS; MORTALITY; NOTE; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SKIN TUMOR;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; HUMANS; INTERFERON ALFA-2A; MELANOMA; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; SKIN NEOPLASMS;

EID: 0032572127     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)78608-6     Document Type: Note

References (11)

1. A Breslow Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma Ann Surg 172 1970 902 909
2. DL Morton LJ Foshag DS Hoon Prolongation of survival in metastatic melanoma ater active specific immunotherapy with a new polyvalent melanoma vaccine Ann Surg 216 1992 463 482
3. CM Balch DS Reintgen JM Kirkwood A Houghton L Peters KK Ang Cutaneous melanoma VT Devita S Hellman SA Rosenberg Cancer principles and practices of oncology 5th ed. 1997 Lippincott-Raven Philadelphia 1947 1994
4. D Reintgen CM Balch JM Kirkwood M Ross Recent advances in the care of the patient with malignant melanoma Ann Surg 1 1997 1 14
5. JM Kirkwood MH Strawderman MS Ernstoff TJ Smith EC Borden RH Blum Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 J Clin Oncol 14 1996 7 17
6. BE Hillner JM Kirkwood MB Atkins ER Johnson TJ Smith Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from ECOG 1684 J Clin Oncol 15 1997 2351 2358
7. BF Cole RD Gelber JM Kirkwood A Goldhirsch E Barylak E Borden A quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment for high-risk resected cutaneous melanoma: Eastern Cooperative Oncology Group Study (E1684) J Clin Oncol 14 1996 2666 2673
8. ET Creagan RJ Dalton 'DL Ahmann Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma J Clin Oncol 13 1995 2776 2783
9. N Cascinelli Evaluation of efficacy of adjuvant rIFNa 2A in melanoma patients with regional node metastasesl Proc ASCO 14 1995 A129
10. H Pehamberger P Soyer A Steiner Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma J Clin Oncol 16 1998 1425 1429
11. RAB Ezekowitz D Phil JB Mulliken J Folkman Interferon alfa-2a therapy for life-threatening hemangiomas of infancy N Engl J Med 326 1992 1456 1463